Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.43 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.43 |
| ▸ | APAF1 | O14727 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8771238 | 0.93 | TDP1 (0.55) | TDP1LMNAHSD17B10L3MBTL1MAPT | |
| SCHEMBL8771242 | 0.93 | TDP1 (0.55) | TDP1LMNAHSD17B10L3MBTL1MAPT | |
| SCHEMBL8770998 | 0.89 | TDP1 (0.55) | TDP1LMNAHSD17B10L3MBTL1MAPT | |
| SCHEMBL8770984 | 0.89 | TDP1 (0.55) | TDP1LMNAHSD17B10L3MBTL1MAPT | |
| SCHEMBL11183173 | 0.88 | TDP1 (0.68) | TDP1LMNAHSD17B10L3MBTL1MAPT | |
| SCHEMBL11183181 | 0.88 | TDP1 (0.68) | TDP1LMNAHSD17B10L3MBTL1MAPT | |
| SCHEMBL8771017 | 0.87 | TDP1 (0.53) | TDP1LMNAHSD17B10L3MBTL1MAPT | |
| SCHEMBL8771030 | 0.87 | TDP1 (0.53) | TDP1LMNAHSD17B10L3MBTL1MAPT | |
| SCHEMBL8771123 | 0.86 | MAPK1 (0.60) | TDP1LMNAHSD17B10L3MBTL1MAPT | |
| SCHEMBL8771107 | 0.86 | TDP1 (0.50) | TDP1LMNAHSD17B10L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1333836-A4 | CEPHALOSPORIN ANTIBIOTICS AND PRODRUGS THEREOF | ESSENTIAL THERAPEUTICS INC (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1333836-A2 | CEPHALOSPORIN ANTIBIOTICS AND PRODRUGS THEREOF | Essential Therapeutics, Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6599893-B2 | Such as (7R)-7-(2-(2-amino-5-chlorothiazol-4-yl)-2-trityl-oxyiminoacetylamino)-3-(4 -methyl-(1,2, 3)thiadiazol-5-ylsulfanyl)-8-oxo-5-thia-1-aza-bicyclo(4.2.0)oct-2-ene-2 -carboxylic acid benzhydryl ester; methicillin-resistance | ESSENTIAL THERAPEUTICS, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20020115650-A1 | Cephalosporin antibiotics and prodrugs thereof | MICROCIDE PHARMACEUTICALS. | 2002-08-22 | — | — | US | disclosed |
| WO-2002017854-A2 | CEPHALOSPORIN ANTIBIOTICS AND PRODRUGS THEREOF | ESSENTIAL THERAPEUTICS, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115650-A1 | Cephalosporin antibiotics and prodrugs thereof | PEPD, ABCG2, ABCC1 | TDP1 2967/4885LMNA 3499/4885HSD17B10 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.